CRNX

Summary

Our analysis recommends selling CRNX immediately and liquidating 100% in a single block via limit orders near recent highs benchmarked to short-term moving averages; avoid market orders on zero-volume prints and accept settlement for any unfilled remainder rather than holding for the remaining 0.65% upside. Implied volatility at 12.5% is crushed with wide spreads and no borrow available, so no new longs or options are warranted. Proceeds should be redeployed aggressively to VRTX to retain exposure to the PALSONIFY/atumelnant platform with a $5B peak opportunity and superior liquidity. The exit window is 1-5 days before delisting; upside is capped to the upper Bollinger Band while downside risk extends to the middle band and 10.7% lower on settlement dislocation if the position is held.

The case

All three analysts and the Research Manager converge: CRNX is terminal post Vertex ~$10B acquisition completed Sept 1, 2026. Standalone thesis extinguished - price pinned at 84.95, 52W high 85.01, analyst target 85.50 = only 0.65% upside. Technicals confirm no tradable momentum: July 7 +98.7% gap on 80.9M shares then 30 sessions compressed 83.72-84.95, RSI 89.79 extreme overbought, MACD hist -0.81 bearish divergence, BB bandwidth 1.29, ATR 0.38, Sept 1 zero-volume 84.95 OHLC flat, volume collapsed to 479k-1.1M, IV 12.5%, put/call OI 0.44. SMAs (50SMA 75.83, 200SMA 50.65) are gap-distorted artifacts, not support. Fundamentals (Q2 revenue 25.12M +134% QoQ, gross profit 24.96M, but -120M net loss, -95M FCF, P/B 7.54, 1.2B cash) now accrue to VRTX, not CRNX. Sentiment 4-0 bullish, confidence 68 is thin-sample merger-arb, not momentum. Risk/reward is negative: 0.28 to BB upper vs 0.36 to BB mid, with delisting/settlement friction and no volatility premium. Conservative correctly flags capital preservation, Aggressive correctly reframes as velocity-of-capital - every day in ATR 0.38 dead tape is opportunity cost vs compounding in VRTX which now owns the rare endocrine platform. Neutral's caution on execution is valid - do not expect 85.23 fills, hit bids at 84.77-84.95 and pay spread rather than phase slowly and get trapped in corporate action processing. No prior CRNX history to calibrate against. Sell captures 98.7% gap gain and redeploys to liquid growth.

What would weaken it

• Delisting and settlement friction may trap remaining shares
• Dead tape with crushed 12.5% IV offers no volatility premium
• Opportunity cost vs compounding in liquid VRTX platform